What is the recommended treatment for resistant cutaneous yeast dermatitis?

Treatment for Resistant Yeast Dermatitis

For fluconazole-refractory cutaneous yeast dermatitis, use itraconazole solution 200 mg once daily OR posaconazole suspension 400 mg twice daily for 3 days then 400 mg daily, for up to 28 days 1.

Treatment Algorithm for Resistant Cases

First-Line Options for Fluconazole-Refractory Disease

The IDSA 2016 guidelines provide strong recommendations with moderate-quality evidence for resistant mucocutaneous candidiasis 1:

• Itraconazole solution: 200 mg once daily for up to 28 days
• Posaconazole suspension: 400 mg twice daily for 3 days, then 400 mg daily for up to 28 days

These are the preferred oral azoles when fluconazole fails, as they maintain antifungal activity against azole-resistant Candida species while avoiding systemic toxicity.

Second-Line Alternatives

If the above options fail or are not tolerated 1:

• Voriconazole: 200 mg twice daily (strong recommendation; moderate-quality evidence)
• Amphotericin B deoxycholate oral suspension: 100 mg/mL 4 times daily (strong recommendation; moderate-quality evidence)

Severe or Refractory Cases Requiring IV Therapy

When oral therapy fails completely 1:

• IV echinocandins (weak recommendation; moderate-quality evidence):
  • Caspofungin: 70 mg loading dose, then 50 mg daily
  • Micafungin: 100 mg daily
  • Anidulafungin: 200 mg loading dose, then 100 mg daily
• IV amphotericin B deoxycholate: 0.3 mg/kg daily

Critical Management Considerations

Address Underlying Causes

The guidelines emphasize that resistance often reflects host factors rather than true microbial resistance 1:

• HIV-infected patients: Initiate or optimize antiretroviral therapy (strong recommendation; high-quality evidence) - this is the single most important intervention to reduce recurrent infections
• Immunosuppression: Reduce corticosteroids or other immunosuppressive medications when possible
• Denture-related candidiasis: Disinfect dentures in addition to antifungal therapy (strong recommendation; moderate-quality evidence)

Common Pitfalls to Avoid

1. Don't use chronic suppressive therapy routinely - it's usually unnecessary and promotes resistance 1. Only consider fluconazole 100 mg three times weekly if recurrent infections persist despite addressing underlying causes.

2. Distinguish true resistance from treatment failure - Most "resistant" dermatophyte infections are actually due to poor adherence, inadequate treatment duration, or reinfection 2. However, for Candida species, true azole resistance can occur through efflux pumps or altered target enzymes 2.

3. Species-specific considerations:

   • C. glabrata: Often fluconazole-resistant; requires higher doses (800 mg daily) or alternative agents 1
   • C. krusei: Intrinsically fluconazole-resistant; use voriconazole, echinocandins, or amphotericin B 1

Duration of Therapy

Continue treatment until complete clinical resolution 1. For resistant cases, this typically means the full 28-day course rather than the standard 7-14 days used for fluconazole-responsive infections.

Important Distinction: Dermatophytes vs. Yeast

The evidence provided focuses primarily on Candida (yeast) infections. If dealing with resistant dermatophyte infections (Trichophyton, etc.), the approach differs significantly 3, 4:

• Terbinafine resistance is emerging (2% prevalence in Japan) due to SQLE gene mutations
• For terbinafine-resistant dermatophytes, use non-SQLE azoles like luliconazole or lanoconazole topically, or oral fosravuconazole
• However, the question specifically asks about "yeast dermatitis," which refers to Candida or Malassezia species

For Malassezia-related conditions (seborrheic dermatitis, pityriasis versicolor), azole agents remain first-line 5, 2, though emerging evidence suggests the pathogenesis may be more immune-mediated than previously thought 6.